Skip to content
stoqly
en

Popular

All languages

Figures come from SEC filings, which are in English. Company and industry names stay as filed.

$ USD

Popular

All currencies

Data is in US dollars, converted at the ECB reference rate of Oct 23, 2026.

Immunovant, Inc.

IMVT Nasdaq Biological Products, (No Diagnostic Substances) Financials FY2019โ€“FY2026

Last close ยท Oct 23, 2026

$28.41

2.4%
Compare
Revenue Total sales reported in the income statement.
โ€”
vs prior year
Operating margin Operating income as a share of revenue.
โ€”
Net income Profit after all expenses, interest and tax.
โˆ’$506M
Free cash flow Cash from operations minus capital spending.
โˆ’$407M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
โ€”
Market cap Last close times the latest diluted share count, so it is approximate.
$5.8B
Oct 23 close
P/E Last close divided by diluted earnings per share over the last four quarters.
โ€”
On โˆ’$2.81 EPS (TTM)

What Immunovant, Inc. does

No business description yet.

Legal name
Immunovant, Inc.
Fiscal year ends
March 31, 2026
Latest annual report
10-K ยท May 20, 2026
Accession ยท CIK
0001764013-26-000064
0001764013

Revenue and margins

Immunovant, Inc. had โ€” of revenue in fiscal 2026.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was โˆ’$407M in fiscal 2026, โ€” of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Immunovant, Inc. returned โ€” to shareholders in fiscal 2026. The diluted share count rose 20.4%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Immunovant, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments $494M$377M$635M$714M$902M
Current ratio 11.5x9.3x13.7x11.2x9.1x
Quick ratio 11.5x9.3x13.7x11.2x9.1x
Total assets $516M$406M$666M$776M$957M
Total liabilities $45.7M$43.3M$48.6M$68.8M$104M
Shareholders' equity $470M$362M$618M$707M$853M
Net debt (โˆ’ = net cash) โ€”โ€”โ€”โ€”โ€”

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. โ€œPlanโ€ marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

โ€”

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8โ€“9 is strong, 0โ€“2 weak.

TestFY19FY20FY21FY22FY23FY24FY25FY26
Net income is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Cash from operations is positive โœ• โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Return on assets rose โ€” โœ“ โœ“ โœ• โœ• โœ“ โœ• โœ“
Cash from operations exceeds net income โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“ โœ“
Debt fell relative to assets โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Current ratio rose โ€” โœ• โœ“ โœ• โœ• โœ“ โœ• โœ•
Share count didn't rise โ€” โœ• โœ• โœ• โœ• โœ• โœ• โœ•
Gross margin rose โ€” โ€” โ€” โ€” โ€” โ€” โ€” โ€”
Revenue rose relative to assets โ€” โ€” โ€” โ€” โœ“ โœ“ โ€” โ€”
F-score โ€” / 3โ€” / 6โ€” / 6โ€” / 62 / 74 / 7โ€” / 6โ€” / 6
Accruals ratio โˆ’0.4%โˆ’21.2%โˆ’9.2%โˆ’10.9%โˆ’4.9%โˆ’8.4%โˆ’5.3%โˆ’11.3%
Altman Z'' โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”

8 years of figures

Amounts in USD. Hover a ratioโ€™s name for its definition.

Download CSV
Fiscal yearFY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue โ€” โ€” โ€” $0.0M $7.6M $24.9M โ€” โ€”
Net interest income โ€” โ€” โ€” $0.0M $7.6M $24.9M โ€” โ€”
Research and development $25.7M $47.9M $68.6M $102M $160M $213M $361M $457M
Interest expense โ€” $0.6M $0.0M โ€” โ€” โ€” โ€” โ€”
Pretax income โˆ’$28.6M โˆ’$66.3M โˆ’$108M โˆ’$157M โˆ’$211M โˆ’$259M โˆ’$413M โˆ’$505M
Income tax $0.0M $0.1M โˆ’$0.4M โˆ’$0.1M $0.0M $0.6M $0.9M $0.2M
Net income โˆ’$28.6M โˆ’$66.4M โˆ’$107M โˆ’$157M โˆ’$211M โˆ’$259M โˆ’$414M โˆ’$506M
Diluted EPS โˆ’$1.29 โˆ’$1.54 โˆ’$1.22 โˆ’$1.43 โˆ’$1.71 โˆ’$1.88 โˆ’$2.73 โˆ’$2.77
Diluted shares 0.02B 0.04B 0.09B 0.11B 0.12B 0.14B 0.15B 0.18B
Cash flow
Cash from operations โˆ’$28.5M โˆ’$53.4M โˆ’$83.3M โˆ’$106M โˆ’$188M โˆ’$214M โˆ’$376M โˆ’$407M
Capital expenditure $0.1M $0.0M $0.2M $0.3M $0.2M $0.4M $0.8M $0.0M
Free cash flow โˆ’$28.6M โˆ’$53.4M โˆ’$83.5M โˆ’$106M โˆ’$188M โˆ’$215M โˆ’$377M โˆ’$407M
Depreciation and amortization $0.0M $0.0M $0.1M $0.1M $0.2M $0.2M $0.4M $0.4M
Stock-based compensation $1.3M $7.0M $18.8M $34.2M $32.3M $41.1M $49.5M $55.7M
Balance sheet
Cash and short-term investments $7.0M $101M $400M $494M $377M $635M $714M $902M
Current assets $12.6M $109M $409M $513M $404M $666M $768M $949M
Current liabilities $0.3M $15.3M $18.8M $44.5M $43.3M $48.6M $68.8M $104M
Property and equipment, net $0.1M $0.1M $0.2M $0.3M $0.3M $0.5M $0.8M $0.4M
Total assets $13.8M $109M $412M $516M $406M $666M $776M $957M
Total liabilities $6.5M $15.3M $21.0M $45.7M $43.3M $48.6M $68.8M $104M
Shareholders' equity $7.3M $94.1M $391M $470M $362M $618M $707M $853M
Margins
Net margin โ€” โ€” โ€” โ€” โˆ’2,783.8% โˆ’1,039.5% โ€” โ€”
FCF margin โ€” โ€” โ€” โ€” โˆ’2,486.0% โˆ’860.1% โ€” โ€”
Net interest share of revenue โ€” โ€” โ€” โ€” 100.0% 100.0% โ€” โ€”
Returns
Return on equity โˆ’389.7% โˆ’130.9% โˆ’44.3% โˆ’36.4% โˆ’50.7% โˆ’52.9% โˆ’62.5% โˆ’64.8%
Return on assets โˆ’206.8% โˆ’107.8% โˆ’41.2% โˆ’33.8% โˆ’45.8% โˆ’48.4% โˆ’57.4% โˆ’58.3%
Return on tangible equity โˆ’389.7% โˆ’70.6% โˆ’27.4% โˆ’33.4% โˆ’58.2% โˆ’42.0% โˆ’58.5% โˆ’59.3%
Growth
Revenue growth โ€” โ€” โ€” โ€” โ€” 229.2% โ€” โ€”
Share count change โ€” 94.8% 103.1% 25.0% 12.2% 12.2% 9.8% 20.4%
Financial health
Current ratio 41.9x 7.1x 21.8x 11.5x 9.3x 13.7x 11.2x 9.1x
Quick ratio 41.9x 7.1x 21.8x 11.5x 9.3x 13.7x 11.2x 9.1x
Capital allocation
Capex / revenue โ€” โ€” โ€” โ€” 2.6% 1.4% โ€” โ€”
Stock comp / revenue โ€” โ€” โ€” โ€” 426.2% 164.8% โ€” โ€”
Quality scores
Piotroski F-score โ€” โ€” โ€” โ€” 2.0 4.0 โ€” โ€”
Accruals ratio โˆ’0.4% โˆ’21.2% โˆ’9.2% โˆ’10.9% โˆ’4.9% โˆ’8.4% โˆ’5.3% โˆ’11.3%

Source: SEC EDGAR XBRL filings (CIK 0001764013). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only โ€” not investment advice. Check the original filings before relying on any figure.

โ†‘ โ†“ to move ยท โ†ต to open